Related Experiment Video
Updated: Jul 14, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Holistic oncologic management improves quality of life in driver gene negative advanced NSCLC a latent growth curve
Li-Ling Ma1,2, Jun-Hui Zhang1, Lei Lei1
1Department of Geriatric Oncology, Chongqing University Cancer Hospital, Chongqing University, School of Medicine, Chongqing University, Chongqing, 400030, China.
Abstract:
Associations between holistic oncologic management (HOM) and the trajectory of quality of life (QoL) in patients with non-small cell lung cancer (NSCLC) have not been evaluated, especially the driver-gene-negative NSCLC patients, whose QoL was proved to be poorer. This randomized controlled trial is performed from October 23, 2019, to July 25, 2023. Patients diagnosed with driver-gene-negative NSCLC were enrolled in Chongqing University Cancer Hospital and were classified into 2 groups: the control arm (arm C) and the treatment arm (arm T). The holistic integrative oncologic therapy was strictly implemented in the arm T, focusing on four basic elements: QoL, depression, pain and nutrition. Patients were comprehensively intervened and assessed in 24 consecutive weeks (i.e. four weeks/cycle, six cycles in total). Six-point QoL trajectories were derived from latent growth curve modeling (LGCM) analyses. The QoL was evaluated by the Functional Assessment of Cancer Therapy-Lung (FACT-L). Participants in two groups were 81 and 77, respectively. The HOM was shown to significantly enhance the QoL, alleviate cancer-related pain, and improve nutritional status and mood symptoms in driver-gene-negative NSCLC patients. Notably, younger patients have experienced more significant improvements. HOM improves the QoL in patients with driver-gene-negative advanced NSCLC, especially in patients with younger age. Trial Registration The research was retrospectively registered on 11/11/2024, in the Chinese Clinical Trial Registry (http://www.chictr.org.cn/ChiCTR2400092132).
Related Concept Videos
Cancer Survival Analysis
Treatment Resistant Cancers
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Treatment Resistent Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...